Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.75 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.63 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.62 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.62 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.62 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203840 | 0.87 | NOTUM (0.83) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL22184095 | 0.86 | HSD17B10 (0.67) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL29440297 | 0.85 | HSD17B10 (0.70) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL21107652 | 0.85 | HSD17B10 (0.70) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL24764176 | 0.83 | HSD17B10 (0.71) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL2776090 | 0.83 | HSD17B10 (0.71) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL28631380 | 0.82 | HSD17B10 (0.70) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL26691241 | 0.79 | NOTUM (0.58) | HSD17B10NOTUMKMT2ATSHRSMN1; SMN2 | |
| SCHEMBL7351778 | 0.79 | CA1 (0.77) | HSD17B10NOTUMPDK1PDK2PDK3 | |
| SCHEMBL5547425 | 0.79 | HDAC1 (0.61) | HSD17B10NOTUMSMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | VIVIDION THERAPEUTICS, INC. | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298213-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HSD17B10 3130/4885NOTUM 1646/4885PDK1 4313/4885 |
| US-20200216507-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HSD17B10 3130/4885NOTUM 1646/4885PDK1 4313/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | HSD17B10 3130/4885NOTUM 1646/4885PDK1 4313/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | HSD17B10 3130/4885NOTUM 1646/4885PDK1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.